Targeted RNAi Platform Market to Hit $6.2 Billion by 2036 as GalNAc siRNA Leads
Updated
Updated · futuremarketinsights.com · Aug 1
Targeted RNAi Platform Market to Hit $6.2 Billion by 2036 as GalNAc siRNA Leads
3 articles · Updated · futuremarketinsights.com · Aug 1
Summary
$2.0 billion in 2026 is projected to grow to $6.2 billion by 2036, implying a 12.1% CAGR for targeted RNAi molecule platforms.
12.1% growth is tied to recent commercial RNAi approvals, liver-targeted delivery and easier dosing schedules that make developers more confident in late-stage planning, manufacturing readiness and regulatory review.
GalNAc-conjugated siRNA is expected to hold a 33.4% share in 2026, while hepatic targets take 33.0% and cardiometabolic diseases 30.4%, reflecting RNAi's strongest traction in liver-focused and measurable-endpoint programs.
Biopharmaceutical companies are forecast to account for 33.7% of end users in 2026, with competition centered on Alnylam, Arrowhead, Silence Therapeutics, Dicerna, OliX and Sirnaomics.
The USA is the fastest-growing profiled market at 13.9% CAGR, but extrahepatic delivery challenges and payer demands for proof that biomarker gains improve outcomes still constrain broader adoption.